Who Josh Hexter is
Lifeward appointed Hexter interim CEO effective September 1, 2026, succeeding Mark Grant. He brings nearly three decades of leadership, business development, and operations experience in life sciences.1
Oramed, BrainsWay, and BioLineRx
Hexter was chief operating and business officer of Oramed Pharmaceuticals, chief business officer of BrainsWay, and executive director of corporate in-licensing at BioLineRx, and he has worked in private equity and venture capital. He founded and ran Biosensor Systems Design.1
His Oramed background matters because Lifeward agreed to a deal under which Oramed can own up to 49.99% of the company.2
My priority as Interim CEO will be to build on the Company's established commercial execution strategy and leverage Lifeward's platform across its growing portfolio of rehabilitation technologies.Josh Hexter, Lifeward announcement
Taking over Lifeward
He took over after Lifeward reported second-quarter 2026 revenue up 16% to $6.6 million, its strongest quarter since late 2024.3
Links
Sources
- Lifeward, Lifeward appoints Josh Hexter interim chief executive officer, August 31, 2026, accessed November 1, 2026
- Lifeward, Lifeward reports fourth quarter and full year 2025 financial results, March 18, 2026, accessed November 1, 2026
- Lifeward, Lifeward reports strong second quarter 2026 financial results, August 14, 2026, accessed November 1, 2026
